An antibody-based therapy against IL1RAP efficiently targeted CML LSCs by blocking IL-1 signaling [31], while chronic exposure to IL-1 leads to exhaustion of healthy HSCs [104]. The gene discussed is IL1RAP; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.